The association between the survivin -31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population

Cancer Epidemiology

Volumn 35, Issue 6, 2011, Pages 555-559

  Bayram, Süleyman ^a,b   Akkiz, Hikmet ^b   Bekar, Aynur ^b   Akgöllü, Ersin ^b  

^a ADIYAMAN UNIVERSITY   (Turkey)

^b CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Hepatocellular carcinoma; Survivin; Survivin 31G C polymorphism; Susceptibilty

Indexed keywords

SURVIVIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; SMOKING; TURKEY (REPUBLIC);

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TURKEY; YOUNG ADULT;

EID: 81055130104     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.01.004     Document Type: Article

References (36)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687.
3. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
4. Akkiz H., Bayram S., Bekar A., Akgöllü E., Ozdil B. Relationship between functional polymorphism in the Aurora A gene and susceptibility of hepatocellular carcinoma. J Viral Hepat 2010, 17:668-674.
5. Akkiz H., Bayram S., Bekar A., Akgöllü E., Ozdil B. Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol 2010, 34:298-302.
6. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5:845-856.
7. Melet A., Song K., Bucur O., Jagani Z., Grassian A.R., Khosravi-Far R. Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol 2008, 615:47-79.
8. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009, 15:513-520.
9. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000, 31:1080-1085.
10. Sah N.K., Khan Z., Khan G.J., Bisen P.S. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006, 244:164-171.
11. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
12. Li F., Brattain M.G. Role of the Survivin gene in pathophysiology. Am J Pathol 2006, 169:1-11.
13. Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006, 5:1087-1098.
14. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett 2007, 249:49-60.
15. Ye C.P., Qiu C.Z., Huang Z.X., Su Q.C., Zhuang W., Wu R.L., et al. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterol 2007, 13:6264-6268.
16. Li F., Altieri D.C. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999, 59:3143-3151.
17. Xu Y., Fang F., Ludewig G., Jones G., Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells DNA. Cell Biol 2004, 23:419-429.
18. Jang J.S., Kim K.M., Kang K.H., Choi J.E., Lee W.K., Kim C.H., et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008, 60:31-39.
19. Gazouli M., Tzanakis N., Rallis G., Theodoropoulos G., Papaconstantinou I., Kostakis A., et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 2009, 24:145-150.
20. Borbély A.A., Murvai M., Szarka K., Kónya J., Gergely L., Hernádi Z., et al. Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 2007, 60:303-306.
21. Yang L., Zhu H., Zhou B., Gu H., Yan H., Tang N., et al. The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 2009, 54:1021-1028.
22. Yang X., Xiong G., Chen X., Xu X., Wang K., Fu Y., et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2009, 135:1341-1349.
23. Wang Y.H., Chiou H.Y., Lin C.T., Hsieh H.Y., Wu C.C., Hsu C.D., et al. Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 2009, 73:670-674.
24. Theodoropoulos G.E., Michalopoulos N.V., Panoussopoulos S.G., Taka S., Gazouli M. Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 2010, 39:976-980.
25. Wagner M., Schmelz K., Dörken B., Tamm I. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res 2008, 3:1054-1060.
26. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
27. Tsai J.F., Chang W.Y., Jeng J.E., Ho M.S., Lin Z.Y., Tsai J.H. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 1994, 14:98-102.
28. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the esophagus for bleeding esophageal varices. Br J Surg 1973, 60:646-649.
29. Cheng Z.J., Hu L.H., Huang S.J. Correlation of -31G/C polymorphisms of surviving promoter to tumorigenesis of gastric carcinoma. Ai Zheng 2008, 27:258-263.
30. Islam A., Kageyama H., Takada N., Kawamoto T., Takayasu H., Isogai E., et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623.
31. Hattori M., Sakamoto H., Satoh K., Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001, 169:155-164.
32. Vaira V., Lee C.W., Goel H.L., Bosari S., Languino L.R., Altieri D.C. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 2007, 26:2678-2684.
33. Cho S., Lee J.H., Cho S.B., Yoon K.W., Park S.Y., Lee W.S., et al. Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma. Pathol Int 2010, 60:203-211.
34. Altieri D.C. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 2006, 5:478-482.
35. Chau G.Y., Lee A.F., Tsay S.H., Ke Y.R., Kao H.L., Wong F.H., et al. Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology 2007, 51:204-218.
36. Augello C., Caruso L., Maggioni M., Donadon M., Montorsi M., Santambrogio R., et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 2009, 9:125.